SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study
Document Type
News Article
Abstract
· Dual inhibition by targeting TMPRSS2 and ACE2 from FDA-approved drugs by computational drug-repurposing.
· Virtual screening was carried out by docking to TMPRSS2 (homology of 5TJX) and ACE2 (1R4L)
· Shortlisted alvimopan, arbekacin, dequalinum, fleroxacin, lopinavir, and valrubicin drugs as potential agents as entry inhibitors
· Lopinavir and valrubicin were found superior in terms of dual inhibition and to prevent COVID-19 as entry inhibitors
Publication Date
4-5-2021
Recommended Citation
Nayak, Yogendra; Maity, Swastika; Mehta, Chetan H.; Suresh, Akhil; Nayak, Usha Y.; and Baby, Krishnaprasad, "SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study" (2021). Health collection. 116.
https://impressions.manipal.edu/health-collection/116
